|OncoCyte Submits Application for CLIA Certification of its Laboratory|
March 21, 2017
|Achieving Certification is Key Step for Planned Commercial Launch in the Second Half of 2017
ALAMEDA, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, has submitted its application for CLIA certification of its laboratory, the next step towards its objective of launching the Company’s first commercial product, a lung cancer diagnostic test, in the second half of 2017. ... |
|Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment|
March 21, 2017
|-Newly reported data on sixth and final patient in cohort further confirms previously announced improvements in hand and arm function following dosing-
FREMONT, Calif., March 21, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previousl... |
|BioTime to Present at Oppenheimer 27th Annual Healthcare Conference|
March 20, 2017
|ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing and commercializing products addressing degenerative
diseases, today announced that Russell Skibsted, Chief Financial
Officer, will be presenting at the Oppenheimer 27th Annual
Healthcare Conference at the Westin Grand Central in New York City on
March 21, at 3:55 p.m. Eastern Time.
A webcast of Mr. Skibsted’s ... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|